CRA was retained by the claimant in an arbitration dispute concerning the alleged breach of a non-compete clause in an agreement to distribute a prescription women’s health product in a country in Asia. A CRA life sciences expert provided an expert report regarding the quantum of lost profits suffered by the claimant because of the alleged breach. In computing the estimate of quantum, the CRA Life Sciences team analyzed and addressed questions regarding the timing of market entry and product sales absent the alleged breach as well as the incremental profit per unit sold.
2023 International Arbitration review: Updates and trends
2023 marked a significant surge in activity across diverse sectors such as mining, oil & gas, the energy transition, pharma, and merger disputes. Throughout...